Avanir Pharmaceuticals
 Home  About  Investors  Product R&D  Employment  Contact

AVANIR PHARMACEUTICALS is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

AVANIR'S products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease.

Avanir Producs

Approved Products

product indicator abreva® (docosanol 10% cream)

Investigational Products

product indicator Zenvia™ for PBA
product indicator MIF Inhibitor
product indicator Zenvia™ for Diabetic Peripheral Neuropathic Pain

product indicator Zenvia™ for Pseudobulbar Affect (PBA)


Webcasts

3rd Quarter Fiscal Year 2008 Financial Results
Date: Aug 07, 2008
Begins: 11:00 a.m. ET

Latest News

Aug 15, 2008
AVANIR Receives Nasdaq Staff Determination Letter

Aug 07, 2008
AVANIR Reports Third Quarter Fiscal 2008 Financial Results

Jul 24, 2008
AVANIR Pharmaceuticals Invites Investors to Third Quarter Conference Call

Home | About | Investors | Products | Employment | Contact
© 2002 Avanir Disclosure